




## OncoRisk Panel

A target enrichment panel designed to analyze 31 genes that are associated with Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, Prostate and Lung cancers. Utilizing Next Generation Sequencing, our target enrichment method allows scientists to specifically isolate whole CDS region of oncogenes and thereby increases the sensitivity of detecting genetic mutations



Studies have shown the specific genes carrying mutation have potential risk to develop certain types of cancers. **CDHI** / Hereditary diffuse **GASTRIC CANCER TP53** / Li-Fraumeni syndrome

Lifetime risk of developing cancer BY AGE 80 **MEN** 68% WOMEN

 $\underset{BYAGE\,30}{\text{lifetime risk of developing cancer}} 21\!\sim\!49\,\%$ 

LIFETIMERISK 68~93% lifetime risk of developing cancer

1. Pharoah, P.D., et al., Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric c ancer families. Gastroenterology, 2001. 121(6): p. 1348-53.

2. Hwang, S.J., et al., Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet, 2003. 72 (4): p. 975-83.

## Reference

## **Specifications**

**Targets** 

Covered Region CDS + Intron(Gene fusions)

Target size 97 kb

Target Enrichment In-solution Hybridization

Minimum input DNA > 50ng

Up to 384 indexing available Multiplexing

Compatible platforms All Illumina, Ion Torrent, MGIseq

APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, Assay Genes CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRSS1,

PTEN, RAD50, RAD51C, RAD51D, SLX4, SMAD4, STK11, TP53, VHL